Ensol Biosciences (XKRX:140610) Cash-to-Debt : 0.52 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ensol Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.52.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ensol Biosciences couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ensol Biosciences's Cash-to-Debt or its related term are showing as below:

XKRX:140610' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 1.94 Max: No Debt
Current: 0.52

During the past 10 years, Ensol Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.03. And the median was 1.94.

XKRX:140610's Cash-to-Debt is ranked worse than
84.55% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs XKRX:140610: 0.52

Ensol Biosciences Cash-to-Debt Historical Data

The historical data trend for Ensol Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ensol Biosciences Cash-to-Debt Chart

Ensol Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.92

1.80

1.96

0.99

0.52

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cash-to-Debt	Get a 7-Day Free Trial					4.92	1.80	1.96	0.99	0.52

Competitive Comparison of Ensol Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Ensol Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensol Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Cash-to-Debt falls into.

Ensol Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ensol Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4471.862	/	(8277.62	+	256.442)
	=	0.52

Ensol Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4471.862	/	(8277.62	+	256.442)
	=	0.52

Ensol Biosciences (XKRX:140610) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ensol Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences (XKRX:140610) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines